Skip to main content

Search

Reset all filters
215 Result(s)
Sort by

Shannon Rountos

Shannon Rountos

Shannon Rountos, Head of Newsroom within Corporate Affairs, speaks about her rewarding and fulfilling career in Boehringer Ingelheim.
Simon Heinrich

Simon Heinrich

Simon Heinrich, an automation engineer in the Engineering and Facilities department, provides an in-depth look at working life at Boehringer Ingelheim.
Stefanie Bock Kreilinger

Stefanie Bock Kreilinger

Stefanie Bock-Kreilinger works in the legal department at Boehringer Ingelheim as head of corporate legal medicine, evidence and digital health.
JARDIANCE® (empagliflozin) becomes the first and only approved treatment in Canada for adults with chronic heart failure regardless of ejection fraction

JARDIANCE® (empagliflozin) becomes the first and only approved treatment in Canada for adults with chronic heart failure regardless of ejection fraction

JARDIANCE® is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death and hospitalization for chronic heart failure1 Heart failure represents a significant, growing disease burden
Yanina Donatini

Yanina Donatini

Yanina Donatini, Head of ITM&S Content Production at Boehringer Ingelheim speaks about her 20 years in the company as innovative and diverse.
Thorsten von Goessel

Thorsten von Goessel

Thorsten von Gossel of Engineering & Facilities, describes Boehringer Ingelheim as family business with long-term perspective and wonderful leadership team.
Jan-Erik Schaefer

Jan-Erik Schaefer

Jan Erik, Senior Team Leader in the upstream pharmaceutical production talks about his motivating and fun career at Boehringer Ingelheim.
Purpose Video IT

Purpose Video IT

Agustina Rojo, System Analyst in Buenos Aires, Argentina explains the many career opportunities Boehringer Ingelheim provides its employees.
Ryan Henri Rickards

Ryan Henri Rickards

Ryan Henry Rickards, a senior finance manager for US Animal Health Commercial Controlling team, highlights his career at Boehringer Ingelheim.
Dominik Huber

Dominik Huber

Dominik Huber, Our Head of Upstream Manufacturing in Vienna, Dominik Huber, has built his entire, senior-level career with Boehringer Ingelheim.
Nelli Milosch

Nelli Milosch

Nelli Milosch, a team lead for our field-based medical team in Germany, says that the people is the best thing about working in Boehringer Ingelheim.
EMPA-KIDNEY trial showed significant benefit of JARDIANCE® (empagliflozin) in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people living with chronic kidney disease

EMPA-KIDNEY trial showed significant benefit of JARDIANCE® (empagliflozin) in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people living with chronic kidney disease

EMPA-KIDNEY, the largest and broadest dedicated SGLT2 inhibitor trial in chronic kidney disease, provides new evidence for patients commonly seen in clinical practice 1,2,3 Phase III trial also demonstrated a 14% statistically significant reduction
Meet our Team

Meet our Team

Find all our contact information here as well as information on where you can meet us virtually or in person. You can also find out how to submit your opportunity to our BD&L team
Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction

Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction

Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction